Arbutus Biopharma (ABUS) Expected to Release Quarterly Earnings on Monday

Arbutus Biopharma (NASDAQ:ABUS) is expected to be releasing its Q3 2026 resultson Monday, November 16th. Analysts expect Arbutus Biopharma to announce earnings of ($0.0232) per share and revenue of $1.00 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 19, 2026 at 9:30 AM ET.

Arbutus Biopharma (NASDAQ:ABUS) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). The business had revenue of $1.01 million during the quarter, compared to the consensus estimate of $0.70 million. Arbutus Biopharma had a return on equity of 90.98% and a net margin of 84.22%.

Arbutus Biopharma Trading Down 0.3%

Shares of NASDAQ ABUS opened at $3.65 on Monday. The firm’s 50-day moving average price is $4.58 and its 200-day moving average price is $4.48. The stock has a market capitalization of $723.10 million, a price-to-earnings ratio of 4.62 and a beta of 0.84. Arbutus Biopharma has a 12-month low of $3.50 and a 12-month high of $5.45.

Arbutus Biopharma declared that its Board of Directors has approved a share buyback plan on Friday, August 21st that allows the company to repurchase outstanding shares. This repurchase authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Share repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several research firms recently commented on ABUS. Wall Street Zen lowered Arbutus Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings upgraded Arbutus Biopharma from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, August 26th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Arbutus Biopharma currently has an average rating of “Moderate Buy” and a consensus price target of $5.00.

About Arbutus Biopharma

Arbutus Biopharma Corporation is a biopharmaceutical company focused on developing novel therapies for chronic hepatitis B virus (HBV) infection. Its research is aimed at addressing multiple stages of the HBV lifecycle, with the long-term goal of developing functional cures rather than therapies that only suppress the virus.

The company’s pipeline has included investigational medicines such as AB-729, an RNA interference therapeutic designed to reduce hepatitis B surface antigen, and other antiviral candidates intended to inhibit viral replication.